الفهرس 
List of Contents
List of TablesOnly 14 pages are availabe for public view
 |  | from | 82 |  |  |
| | | from | 82 | | |
Abstract
In this study we aimed to assess frequency of liver dysfunction in recovered COVID19 patients. Also, to evaluate hepatic manifestations post-COVID19 patients. A total of 100 patients; 70 (70%) patients of them had underlying liver disease and the other 30 (30%) patients hadn’t underlying liver diseases.
In the current study, we found that among those patients without underlying liver disease, 6 (20%) patients of patients developed raised liver transaminases and another 3 (10%) patients developed jaundice. All those 9 (30%) patients were completely improved without any hepatic sequel.
The main findings in this study; 1) patients with underlying liver disease had significantly higher mean age, 2) both groups had significant reduction leucocytes and increase lymphocytes during follow up, 3) patients with preexisting liver disease had significantly lower albumin, platelets and lymphocytes and 4) also, preexisting liver disease had significant higher frequency of severe disease, ICU’s admission, non-invasive ventilation and mechanical ventilation with longer stay at ICU.
In conclusion, temporal variations in liver parameters during disease course as well as different patterns of derangement are depicted. More intensive surveillance and individualized therapeutic approaches should be tailored for immunocompromised patients with advanced liver disease.